Topics

CRISPR Therapeutics Takes Over Joint Venture Casebia Therapeutics from Bayer

09:53 EDT 22 Oct 2019 | Speciality Pharma Journal

LEVERKUSEN, Germany and ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 21, 2019 /PRNewswire/ — CRISPR Therapeutics and Bayer today announced proposed plans whereby Casebia Therapeutics, a joint venture between CRISPR Therapeutics and Bayer, would operate under the direct management of CRISPR Therapeutics. Upon closing of the transaction, Casebia Therapeutics would focus on the development of its …

Original Article: CRISPR Therapeutics Takes Over Joint Venture Casebia Therapeutics from Bayer

NEXT ARTICLE

More From BioPortfolio on "CRISPR Therapeutics Takes Over Joint Venture Casebia Therapeutics from Bayer"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...